Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 05, 2009 01:15 ET | Source: Novartis Pharma AG

Novartis begins shipment of Fluvirin® seasonal influenza vaccine for the U.S. market ahead of schedule

Novartis Vaccines ships doses of seasonal influenza vaccine to the U.S. market aided by an expedited FDA review Providing 30 million doses of Fluvirin vaccine in the U.S., to support the...
August 03, 2009 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera rekrutiert letzten Patienten der RHODOS Studie mit Catena® in Leber Hereditären Optikusneuropathie

Liestal, Schweiz, 3. August, 2009 - Santhera Pharmaceuticals (SIX: SANN), ein auf seltene neuromuskuläre Erkrankungen fokussiertes Schweizer Spezialitätenpharmaunternehmen, gibt heute...
August 03, 2009 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera Enrolls Last Patient in RHODOS Study Evaluating Catena® in Leber's Hereditary Optic Neuropathy

Liestal, Switzerland, August 3, 2009 - Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharmaceutical company focused on orphan neuromuscular diseases, announced today that recruitment...
July 27, 2009 04:41 ET | Source: Clariant International Ltd

Reminder: Invitation to Second Quarter / First Half 2009 Results Presentation

Dear Investors and Analysts, Please be reminded that Clariant is to present its Second Quarter / First Half 2009 Results on July 30, 2009. Please find attached all relevant details...
July 24, 2009 06:45 ET | Source: Novartis Pharma AG

Ilaris® recommended for European approval as new biologic drug to treat a rare but serious group of auto-inflammatory diseases

Set to become first medicine in EU to treat patients aged four and older suffering from life-long cryopyrin-associated periodic syndrome (CAPS)[1] Ilaris targets interleukin-1 beta (IL-1ß), a key...
July 21, 2009 01:15 ET | Source: Novartis Pharma AG

FDA approves Tekturna HCT® as initial treatment in patients unlikely to achieve their blood pressure goal with a single agent

Tekturna HCT combines the only approved direct renin inhibitor, Tekturna®, with widely used diuretic, hydrochlorothiazide, in a single pill[1] Data show combination of Tekturna and...
July 16, 2009 00:59 ET | Source: Novartis Pharma AG

Novartis: excellente performance opérationnelle au premier semestre 2009, entraînée par les innovations soutenues de Pharmaceuticals

Pharmaceuticals est un leader de la croissance de l'industrie pharmaceutique: Chiffre d'affaires en hausse de 12% (en monnaies locales) au premier semestre 2009, grâce aux contributions des...
July 16, 2009 00:59 ET | Source: Novartis Pharma AG

Novartis delivers strong operational performance in the first half of 2009 driven by sustained Pharmaceuticals innovation

Pharmaceuticals an industry growth leader: Net sales up 12% (local currencies) in first half of 2009 on contributions from new products and expansion in all regions R&D maintains...
July 16, 2009 00:59 ET | Source: Novartis Pharma AG

Novartis erzielt im ersten Halbjahr 2009 eine starke operative Performance - dank der anhaltenden Innovationskraft der Division Pharmaceuticals

Die Division Pharmaceuticals ist eines der wachstumsstärksten Unternehmen der Branche: Neue Produkte und die Expansion in allen Regionen tragen wesentlich dazu bei, dass der Nettoumsatz im ersten...
July 10, 2009 09:41 ET | Source: Clariant International Ltd

Clariant erzielt Einigung mit Angestelltenvertretung über neuen Sozialplan

Muttenz, 10. Juli, 2009 - Die Geschäftsleitung von Clariant Schweiz und die Angestelltenvertretung ( AV ) haben sich heute auf einen neuen Sozialplan verständigt. Armin Meile, Landesleiter...